Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Daniel Cimbora"'
Autor:
Jeffrey L. Bennett, Sean J. Pittock, Friedemann Paul, Ho Jin Kim, Sarosh R. Irani, Kevin C. O'Connor, Kristina R. Patterson, Michael A. Smith, Michele Gunsior, Nanette Mittereder, William A. Rees, Daniel Cimbora, Bruce A. C. Cree
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 11, Iss 10, Pp 2792-2798 (2024)
Abstract This post hoc analysis of the randomized, placebo‐controlled N‐MOmentum study (NCT02200770) of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD) evaluated relationships between circulating B‐cell subsets and aquaporin‐4
Externí odkaz:
https://doaj.org/article/0428a4d92b3b4cc6b32de98550688c52
Autor:
Ho Jin Kim, Orhan Aktas, Kristina R. Patterson, Schaun Korff, Amy Kunchok, Jeffrey L. Bennett, Brian G. Weinshenker, Friedemann Paul, Hans‐Peter Hartung, Daniel Cimbora, Michael A. Smith, Nanette Mittereder, William A. Rees, Dewei She, Bruce A. C. Cree
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 10, Iss 12, Pp 2413-2420 (2023)
Abstract Inebilizumab, a humanized, glycoengineered, IgG1 monoclonal antibody that depletes CD19+ B‐cells, is approved to treat aquaporin 4 (AQP4) IgG‐seropositive neuromyelitis optica spectrum disorder (NMOSD). Inebilizumab is afucosylated and e
Externí odkaz:
https://doaj.org/article/117e79e5e7134a03b6b3f3c65a13a5f5
Autor:
Cory Perugino, Emma L. Culver, Arezou Khosroshahi, Wen Zhang, Emanuel Della-Torre, Kazuichi Okazaki, Yoshiya Tanaka, Matthias Löhr, Nicolas Schleinitz, Judith Falloon, Dewei She, Daniel Cimbora, John H. Stone
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1795-1808 (2023)
Abstract Introduction Immunoglobulin G4-related disease (IgG4-RD) is a debilitating multiorgan disease characterized by recurring flares leading to organ dysfunction, decreased quality of life, and mortality. Glucocorticoids, the standard of care for
Externí odkaz:
https://doaj.org/article/8fd489c2c4564ecf821166afa716dc2e
Autor:
Jeffrey L. Bennett, Orhan Aktas, William A. Rees, Michael A. Smith, Michele Gunsior, Li Yan, Dewei She, Daniel Cimbora, Sean J. Pittock, Brian G. Weinshenker, Friedemann Paul, Romain Marignier, Dean Wingerchuk, Gary Cutter, Ari Green, Hans-Peter Hartung, Ho Jin Kim, Kazuo Fujihara, Michael Levy, Eliezer Katz, Bruce A.C. Cree
Publikováno v:
EBioMedicine, Vol 86, Iss , Pp 104321- (2022)
Summary: Background: Inebilizumab is an anti-CD19 antibody approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with aquaporin-4 autoantibodies. The relationship between B-cell, plasma-cell (PC), and immunoglobulin d
Externí odkaz:
https://doaj.org/article/790df91e946941298837a5937869bc85
Autor:
Friedemann Paul, Roman Marignier, John Lindsey, Ho Jin Kim, Dewei She, Daniel Cimbora, Kristina Patterson, Bruce Cree
Publikováno v:
Thursday, April 27.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6fe5dd17094f39644295e26f55fdf694
https://doi.org/10.1212/wnl.0000000000202412
https://doi.org/10.1212/wnl.0000000000202412
Autor:
Dewei She, Eliezer Katz, Aram Zabeti, Maureen A. Mealy, Jorn Drappa, Daniel Cimbora, Mary Rensel
Publikováno v:
Multiple Sclerosis Journal. 28:925-932
Background: Efficacy and safety of inebilizumab for treatment of neuromyelitis optica spectrum disorder in adults seropositive for aquaporin-4 (AQP4)–immunoglobulin (Ig) G were demonstrated in the 28-week randomized controlled period of the N-MOmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20a74aecc6e3ad00440196b71da3ce24
https://doi.org/10.1177/13524585211047223
https://doi.org/10.1177/13524585211047223
Publikováno v:
Clinical pharmacokinetics. 61(3)
Background and objective Inebilizumab is a humanized, affinity-optimized, afucosylated immunoglobulin (Ig)-G1κ monoclonal antibody that binds to CD19, resulting in effective depletion of peripheral B cells. It is being developed to treat various aut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0068b666641ef09d24d6112cb3f5709
https://pubmed.ncbi.nlm.nih.gov/34718986
https://pubmed.ncbi.nlm.nih.gov/34718986
Autor:
John N. Ratchford, Romain Marignier, F. Paul, Dewei She, Ian M. Williams, Orhan Aktas, Ari J. Green, Brian G. Weinshenker, Sean J. Pittock, Jorn Drappa, Daniel Cimbora, Eliezer Katz, Hans-Peter Hartung, Fred D. Lublin, Michael E. Smith, Ho Jin Kim, Gary R. Cutter, Dean Wingerchuk, Jeffrey Bennett, William Rees, Kazuko Fujihara, Bruce A.C. Cree
Publikováno v:
Neurology® Neuroimmunology & Neuroinflammation
article-version (Version of Record) 3
article-version (Version of Record) 3
ObjectiveTo assess treatment effects on Expanded Disability Status Scale (EDSS) score worsening and modified Rankin Scale (mRS) scores in the N-MOmentum trial of inebilizumab, a humanized anti-CD19 monoclonal antibody, in participants with neuromyeli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6b4b6c2edf622826973987f354eeb9f
http://europepmc.org/articles/PMC8054974
http://europepmc.org/articles/PMC8054974
Autor:
Friedemann Paul, Ari J. Green, John N. Ratchford, Brian G. Weinshenker, Dewei She, Sean J. Pittock, Orhan Aktas, Ho Jin Kim, Hans-Peter Hartung, Romain Marignier, Jorn Drappa, Jeffrey Bennett, Eliezer Katz, Dean M. Wingerchuk, Daniel Cimbora, Kazuo Fujihara, Bruce A.C. Cree, Gary Cutter, Michael E. Smith, William Rees
Publikováno v:
Multiple Sclerosis and Related Disorders. 57:103356
Background The N-MOmentum trial, a double-blind, randomized, placebo-controlled, phase 2/3 study of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD), enrolled participants who were aquaporin-4-immunoglobulin G (AQP4-IgG)-seropositive (A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5690bb6209cfab28586ce591c946b7a8
https://doi.org/10.1016/j.msard.2021.103356
https://doi.org/10.1016/j.msard.2021.103356
Autor:
Dewei She, Michael J. Levy, Eoin P. Flanagan, Eliezer Katz, Jorn Drappa, Daniel Cimbora, Maureen A. Mealy, Bruce A.C. Cree
Publikováno v:
Multiple Sclerosis and Related Disorders. 57:103352
Background: The B-cell–depleting agent rituximab (anti-CD20) was historically used to prevent attacks in neuromyelitis optica spectrum disorder (NMOSD). Inebilizumab, which targets and depletes CD19-expressing B cells, plasmablasts, and some plasma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d54537c470ae2dcd1ecc640a5dfaa183
https://doi.org/10.1016/j.msard.2021.103352
https://doi.org/10.1016/j.msard.2021.103352